Advancing Multiple Myeloma Care: From Frontline Strategies to Novel Therapies in Relapsed/Refractory Settings​

Kenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Laahn Ho Foster, MD, discusses the potential role of daratumumab plus lenalidomide maintenance in multiple myeloma after ASCT.

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.